Navani Sanjay, Bhaduri Anita S
Department of Surgical Pathology, Breach Candy Hospital and Research Centre, Mumbai.
Indian J Pathol Microbiol. 2005 Apr;48(2):199-201.
The incidence of oestrogen receptor negative and progesterone receptor positive (ER-/PR+) invasive breast carcinoma is reported to be as high as 21% in India, as compared to 3-5% in the western literature. We used automated immunohistochemistry with Biogenex antibodies to re-evaluate the ER status in 37 Indian patients with invasive breast carcinomas previously reported as ER-/PR+ by a different manual staining protocol in two city hospitals. The automated technique utilized different reagents (all US FDA approved for in vitro diagnostic use) and staining protocols from those used in the manual assays. Of the 37 previously ER-tumours, only 9 (24.3%) tumours remained ER-. Twenty-eight (75.6%) tumours were found to be ER+. Our results indicate that the high incidence of ER-/PR+ breast cancer reported from India is most likely due to the use of suboptimal manual assays, rather than true genetic differences. ER expression in breast cancer among Indian women may be much higher than previously believed. These results have important implications for the use of oestrogen modulators such as tamoxifen in developing countries such as India.
据报道，雌激素受体阴性且孕激素受体阳性（ER-/PR+）的浸润性乳腺癌在印度的发病率高达21%，而西方文献报道的这一比例为3%-5%。我们使用Biogenex抗体进行自动免疫组织化学检测，对37例印度浸润性乳腺癌患者的雌激素受体（ER）状态进行重新评估，这些患者之前在两家城市医院采用不同的手工染色方案被报告为ER-/PR+。自动技术使用的试剂（均经美国食品药品监督管理局批准用于体外诊断）和染色方案与手工检测所用的不同。在之前检测为ER-的37个肿瘤中，只有9个（24.3%）肿瘤仍为ER-。28个（75.6%）肿瘤被发现为ER+。我们的结果表明，印度报道的ER-/PR+乳腺癌的高发病率很可能是由于使用了次优的手工检测方法，而非真正的基因差异。印度女性乳腺癌中的ER表达可能比之前认为的要高得多。这些结果对在印度等发展中国家使用他莫昔芬等雌激素调节剂具有重要意义。
